NCT00159679

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 167 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if changes in nerve function happen during the study.

Conditions

• Diabetic Neuropathy, Painful

Interventions

Type	Name	Description
DRUG	Pregabalin

Timeline

• Start date: 2004-09-01
• Completion: 2005-10-01
• First posted: 2005-09-12
• Last updated: 2021-01-25

Locations

30 sites across 1 country: United States